Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas

Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas - Single-center Pilot Study of 32 Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05107843

Acronym

SARCOMAS

Enrollment

Registered

2021-11-04

Start date

2020-02-01

Completion date

2021-12-31

Last updated

2021-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma in Children

Keywords

Osteosarcoma, Necrosis, Immunohistochemical markers of hypoxia, Hypoxia, Chemotherapy, Metastasis

Brief summary

The aim of this pilot study is therefore to retrospectively measure the volume and percentage of necrosis on diagnostic MRI in T1 sequence and in parallel to study the expression of immunohistochemical markers of hypoxia (HIF-1α, CAIX , HIF-2α, pS6, phosphomTor, CD163 and CD68) on diagnostic biopsies of high-grade osteosarcomas from 2007 to 2018 in the Strasbourg center, focusing on the pediatric population. The investigators will systematically carry out a correlation analysis between these different parameters and with the clinical data of these same patients (response to chemotherapy, presence of metastases or not and overall and recurrence-free survival). This will eventually make it possible to highlight new prognostic markers at diagnosis.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 20 Years

Inclusion criteria

* Subject ≤ 20 years at diagnosis * Subject having been treated for osteosarcoma in the OS2006 protocol or treated according to * Supported at Strasbourg University Hospitals between 05/01/2007 and 10/31/2018 * Availability of its diagnostic tumor material stored in paraffin * having an MRI diagnostic evaluation comprising the injected T1 sequences necessary for the analysis of the volume / necrotic proportion.

Exclusion criteria

* Opposition of the patient (or his legal representatives if he is a minor) to participate in the study * Diagnosis other than osteosarcoma * Biological tissue from a patient who does not meet all the inclusion criteria * Patient under legal protection * Patient under guardianship or guardianship

Design outcomes

Primary

Measure	Time frame
Retropsective study of pediatric osteosarcomas	Files analysed retrospectively from January 01, 2007 to December 31, 2018 will be examined]

Countries

France

Contacts

Primary ContactNatacha ENTZ-WERLE, MD, PhD

Natacha.Entz-Werle@chru-strasbourg.fr33.3.88.12.80.96

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results